Active, not recruitingPhase 3NCT02466971
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
Studying Adenocarcinoma of the cervix uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Charles A LeathNRG Oncology
- Intervention
- Brachytherapy(radiation)
- Enrollment
- 450 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2016 – 2026
Study locations (30)
- University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
- Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
- Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
- Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
- Alaska Women's Cancer Care, Anchorage, Alaska, United States
- Anchorage Oncology Centre, Anchorage, Alaska, United States
- Katmai Oncology Group, Anchorage, Alaska, United States
- Providence Alaska Medical Center, Anchorage, Alaska, United States
- Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
- Banner University Medical Center - Tucson, Tucson, Arizona, United States
- University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
- CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States
- Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
NRG Oncology
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02466971 on ClinicalTrials.govOther trials for Adenocarcinoma of the cervix uteri
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07276360Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in UgandaUganda Cancer Institute
- RECRUITINGPHASE1NCT07454642AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid TumorsAvacta Life Sciences Ltd
- RECRUITINGPHASE3NCT07061977Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical CancerNational Cancer Institute (NCI)
- RECRUITINGNCT07359586Laryngopharyngeal Injury After Endotracheal Intubation Under General AnesthesiaZhejiang University
- RECRUITINGPHASE1NCT07020117A Study of [225Ac]Ac-AKY-1189 in Patients With Solid TumorsAktis Oncology, Inc.
- RECRUITINGPHASE2NCT06654011IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 TrialUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT07153952RT for Adenocarcinoma/Adenosquamous CarcinomaPeking Union Medical College Hospital
- RECRUITINGNCT06733740Ultrasound-guided Thermal Ablation for Papillary Thyroid CarcinomaChinese PLA General Hospital